

# Elisa Gremese

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3471866/publications.pdf>

Version: 2024-02-01

215  
papers

6,354  
citations

76196

40  
h-index

95083

68  
g-index

222  
all docs

222  
docs citations

222  
times ranked

8796  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 963-974.	5.2	348
2	Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. <i>Nature Medicine</i> , 2020, 26, 1295-1306.	15.2	304
3	Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 172-175.	0.5	172
4	Obesity and reduction of the response rate to anti-tumor necrosis factor $\hat{\pm}$ in rheumatoid arthritis: An approach to a personalized medicine. <i>Arthritis Care and Research</i> , 2013, 65, 94-100.	1.5	170
5	MicroRNA-155 at the Critical Interface of Innate and Adaptive Immunity in Arthritis. <i>Frontiers in Immunology</i> , 2017, 8, 1932.	2.2	170
6	Post-COVID-19 global health strategies: the need for an interdisciplinary approach. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 1613-1620.	1.4	167
7	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012, 12, 225-229.	2.5	146
8	Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2019, 71, 599-611.	2.9	142
9	Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. <i>Rheumatology</i> , 2015, 54, 891-898.	0.9	129
10	Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 858-862.	0.5	112
11	Obesity as a Risk and Severity Factor in Rheumatic Diseases (Autoimmune Chronic Inflammatory) $T_j$ ETQq1 1 0.784314 rgBT / Overload	2.2	110
12	Body weight, gender and response to TNF-blockers in axial spondyloarthritis. <i>Rheumatology</i> , 2014, 53, 875-881.	0.9	104
13	Interleukin-1 $\hat{2}$ and Interleukin-6 in Arthritis Animal Models: Roles in the Early Phase of Transition from Acute to Chronic Inflammation and Relevance for Human Rheumatoid Arthritis. <i>Molecular Medicine</i> , 2010, 16, 552-557.	1.9	100
14	MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12970.	5.8	97
15	The metabolic syndrome: The crossroads between rheumatoid arthritis and cardiovascular risk. <i>Autoimmunity Reviews</i> , 2011, 10, 582-589.	2.5	90
16	Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. <i>Rheumatology</i> , 2012, 51, 157-168.	0.9	89
17	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 369.	1.6	89
18	Longterm Retention of Tumor Necrosis Factor-Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors. <i>Journal of Rheumatology</i> , 2012, 39, 1179-1184.	1.0	87

#	ARTICLE	IF	CITATIONS
19	IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. <i>Pharmacogenomics</i> , 2006, 7, 683-695.	0.6	75
20	Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. <i>Internal Medicine Journal</i> , 2020, 50, 1085-1090.	0.5	75
21	MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. <i>Nature Communications</i> , 2017, 8, 15877.	5.8	72
22	Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1292-1295.	0.5	71
23	Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA. <i>Frontiers in Immunology</i> , 2018, 9, 1936.	2.2	71
24	Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1228-1236.	0.5	70
25	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , 2014, 53, 2209-2213.	0.9	67
26	Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment. <i>Clinical Rheumatology</i> , 2017, 36, 2151-2158.	1.0	67
27	Sarilumab use in severe SARS-CoV-2 pneumonia. <i>EClinicalMedicine</i> , 2020, 27, 100553.	3.2	66
28	Tapering and discontinuation of TNF- $\pm$ blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. <i>Arthritis Research and Therapy</i> , 2016, 18, 39.	1.6	62
29	Predicting <sc>In-Hospital</sc> Mortality in <sc>COVID</sc> $\geq$ 19 Older Patients with Specifically Developed Scores. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 37-43.	1.3	62
30	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. <i>Arthritis and Rheumatology</i> , 2020, 72, 1314-1324.	2.9	58
31	Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. <i>Clinical Immunology</i> , 2011, 138, 107-116.	1.4	55
32	<i>Porphyromonas gingivalis</i> and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue. <i>Arthritis Research and Therapy</i> , 2013, 15, R66.	1.6	55
33	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 449-56.	0.4	55
34	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016, 3, e000163.	1.1	51
35	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1079-1088.	0.6	50
36	Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease. <i>Autoimmunity Reviews</i> , 2019, 18, 565-575.	2.5	49

#	ARTICLE	IF	CITATIONS
37	Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. <i>Microvascular Research</i> , 2021, 133, 104071.	1.1	49
38	Safety of Etanercept and Methotrexate in Patients with Rheumatoid Arthritis and Hepatitis C Virus Infection: A Multicenter Randomized Clinical Trial. <i>Journal of Rheumatology</i> , 2014, 41, 286-292.	1.0	47
39	Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. <i>Arthritis Research and Therapy</i> , 2018, 20, 75.	1.6	45
40	PTPN22 1858C>T Polymorphism Distribution in Europe and Association with Rheumatoid Arthritis: Case-Control Study and Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e24292.	1.1	43
41	Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis. <i>Medicine (United States)</i> , 2017, 96, e6656.	0.4	43
42	Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. <i>European Journal of Internal Medicine</i> , 2019, 60, 46-53.	1.0	43
43	The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 869-77.	0.4	42
44	An autosomal recessive <i>DNASE1L3</i> -related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus. <i>Lupus</i> , 2017, 26, 768-772.	0.8	40
45	COVID-19 and intestinal inflammation: Role of fecal calprotectin. <i>Digestive and Liver Disease</i> , 2020, 52, 1231-1233.	0.4	40
46	Positive RT-PCR nasopharyngeal swab in patients recovered from COVID-19 disease: When does quarantine really end?. <i>Journal of Infection</i> , 2020, 81, e1-e3.	1.7	40
47	One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 813-821.	1.4	40
48	Comparative analysis of synovial inflammation after SARS-CoV-2 infection. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e91-e91.	0.5	40
49	JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. <i>Journal of Leukocyte Biology</i> , 2019, 106, 1063-1068.	1.5	38
50	Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics register GISEA. <i>Clinical Rheumatology</i> , 2018, 37, 315-321.	1.0	37
51	Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid Arthritis. <i>EBioMedicine</i> , 2015, 2, 2037-2045.	2.7	36
52	Assessment of neurological manifestations in hospitalized patients with COVID-19. <i>European Journal of Neurology</i> , 2020, 27, 2322-2328.	1.7	36
53	Preliminary Classification of Nonmalignant B Cell Proliferation in Sjögren's Syndrome: Perspectives on Pathobiology and Treatment Based on an Integrated Clinico-Pathologic and Molecular Study Approach. <i>Blood Cells, Molecules, and Diseases</i> , 2001, 27, 757-766.	0.6	35
54	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	1.6	35

#	ARTICLE	IF	CITATIONS
55	COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes. JCI Insight, 2021, 6, .	2.3	35
56	Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. Rheumatology, 2020, 59, 2523-2533.	0.9	35
57	Biomarkers of Good EULAR Response to the B Cell Depletion Therapy in All Seropositive Rheumatoid Arthritis Patients: Clues for the Pathogenesis. PLoS ONE, 2012, 7, e40362.	1.1	34
58	Predictive Factors for a New Positive Nasopharyngeal Swab Among Patients Recovered From COVID-19. American Journal of Preventive Medicine, 2021, 60, 13-19.	1.6	34
59	Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. United European Gastroenterology Journal, 2019, 7, 1189-1197.	1.6	31
60	Thrombogenicity of TNF $\pm$ in rheumatoid arthritis defined through biological probes: TNF $\pm$ blockers. Autoimmunity Reviews, 2004, 3, 261-266.	2.5	30
61	Prevalence and Determinants of Peripheral Microvascular Endothelial Dysfunction in Rheumatoid Arthritis Patients: A Multicenter Cross-Sectional Study. Mediators of Inflammation, 2018, 2018, 1-8.	1.4	30
62	ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Research and Therapy, 2009, 11, R163.	1.6	29
63	Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells. Clinical and Experimental Immunology, 2018, 193, 13-23.	1.1	29
64	Quantitative and semi-quantitative computed tomography analysis of interstitial lung disease associated with systemic sclerosis: A longitudinal evaluation of pulmonary parenchyma and vessels. PLoS ONE, 2019, 14, e0213444.	1.1	28
65	Loss of $\pm$ 2-6 sialylation promotes the transformation of synovial fibroblasts into a pro-inflammatory phenotype in arthritis. Nature Communications, 2021, 12, 2343.	5.8	28
66	Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients. RMD Open, 2021, 7, e001681.	1.8	28
67	B-Cell Subsets in the Joint Compartments of Seropositive and Seronegative Rheumatoid Arthritis (RA) and No-RA Arthritides Express Memory Markers and ZAP70 and Characterize the Aggregate Pattern Irrespectively of the Autoantibody Status. Molecular Medicine, 2011, 17, 901-909.	1.9	27
68	Temporal ultrasonography findings in temporal arteritis: early disappearance of halo sign after only 2 days of steroid treatment. Rheumatology, 2013, 52, 622-622.	0.9	26
69	Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. Infection, 2020, 48, 767-771.	2.3	26
70	Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors. Journal of Autoimmunity, 2020, 108, 102397.	3.0	26
71	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IBD study. Digestive and Liver Disease, 2019, 51, 972-977.	0.4	25
72	Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 416-419.	0.5	24

#	ARTICLE	IF	CITATIONS
73	Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. <i>Rheumatology</i> , 2018, 57, vii42-vii53.	0.9	24
74	Synovial Predictors of Differentiation to Definite Arthritis in Patients With Seronegative Undifferentiated Peripheral Inflammatory Arthritis: microRNA Signature, Histological, and Ultrasound Features. <i>Frontiers in Medicine</i> , 2018, 5, 186.	1.2	24
75	What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19?. <i>Autoimmunity Reviews</i> , 2020, 19, 102666.	2.5	24
76	Polymorphisms of the IgH enhancer HS1.2 and risk of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1309-1315.	0.5	23
77	Chemerin and PEDF Are Metaflammation-Related Biomarkers of Disease Activity and Obesity in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 207.	1.2	23
78	Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 116.	1.6	23
79	Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve. <i>Endocrine</i> , 2019, 63, 369-375.	1.1	23
80	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLISS-LN). Results from a large, nationwide, multicentric cohort. <i>Journal of Autoimmunity</i> , 2021, 124, 102729.	3.0	23
81	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. <i>Rheumatology</i> , 2015, 54, 1074-1079.	0.9	22
82	Inclusion of Synovial Tissue-Derived Characteristics in a Nomogram for the Prediction of Treatment Response in Treatment-Naive Rheumatoid Arthritis Patients. <i>Arthritis and Rheumatology</i> , 2021, 73, 1601-1613.	2.9	22
83	Position paper of Italian rheumatologists on the use of biosimilar drugs. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 1-4.	0.4	22
84	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. <i>Joint Bone Spine</i> , 2014, 81, 508-512.	0.8	21
85	Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. <i>Rheumatology</i> , 2020, 59, 3731-3736.	0.9	21
86	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020, 7, 42.	1.2	21
87	Telemedicine will not keep us apart in COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e48-e48.	0.5	21
88	B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1150-1153.	1.8	20
89	Hepatocyte growth factor and transforming growth factor $\beta$ 1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 3633-3639.	6.7	20
90	Memory B cell subsets and plasmablasts are lower in early than in long-standing Rheumatoid Arthritis. <i>BMC Immunology</i> , 2014, 15, 28.	0.9	20

#	ARTICLE	IF	CITATIONS
91	Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons. <i>Autoimmunity Reviews</i> , 2017, 16, 1096-1102.	2.5	20
92	Immune-Guided Therapy of COVID-19. <i>Cancer Immunology Research</i> , 2022, 10, 384-402.	1.6	20
93	Rheumatoid arthritis and Alzheimer's disease: genetic and epigenetic links in inflammatory regulation. <i>Discovery Medicine</i> , 2012, 14, 379-88.	0.5	20
94	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016, 35, 2649-2656.	1.0	19
95	B cell activating factor (BAFF) and BAFF receptors: fakes and facts. <i>Clinical and Experimental Immunology</i> , 2017, 190, 291-292.	1.1	19
96	Relationship between the tumor necrosis factor receptor II (TNF-RII) gene polymorphism and sTNF-RII plasma levels in healthy controls and in rheumatoid arthritis. <i>Human Immunology</i> , 2004, 65, 1420-1426.	1.2	18
97	Biomolecular features of inflammation in obese rheumatoid arthritis patients: management considerations. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 751-762.	1.3	18
98	Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu. <i>Journal of Clinical Pathology</i> , 2018, 71, 620-625.	1.0	18
99	Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis. <i>Swiss Medical Weekly</i> , 2011, 141, w13211.	0.8	18
100	Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 823-830.	0.5	18
101	The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor. <i>Clinical and Experimental Immunology</i> , 2016, 184, 62-72.	1.1	17
102	The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2017, 2017, 1-11.	1.4	17
103	The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. <i>Rheumatology</i> , 2018, 57, vii11-vii22.	0.9	17
104	Overweight/obesity affects histological features and inflammatory gene signature of synovial membrane of Rheumatoid Arthritis. <i>Scientific Reports</i> , 2019, 9, 10420.	1.6	17
105	The pathogenesis of microthrombi in COVID-19 cannot be controlled by DOAC: NETosis should be the target. <i>Journal of Internal Medicine</i> , 2021, 289, 420-421.	2.7	17
106	Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1419-1428.	0.5	17
107	Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 829-34.	1.4	16
108	Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations. <i>Clinical Immunology</i> , 2020, 214, 108395.	1.4	16



#	ARTICLE	IF	CITATIONS
109	Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA). <i>Internal and Emergency Medicine</i> , 2011, 6, 11-15.	1.0	15
110	Detection of bone erosions in early rheumatoid arthritis: 3D ultrasonography versus computed tomography. <i>Clinical Rheumatology</i> , 2015, 34, 1181-1186.	1.0	15
111	Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. <i>RMD Open</i> , 2018, 4, e000667.	1.8	15
112	Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement. <i>Diagnostics</i> , 2020, 10, 664.	1.3	15
113	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , 2021, 60, 728-736.	0.9	15
114	Haemophilus parasuis (Glaesserella parasuis) as a Potential Driver of Molecular Mimicry and Inflammation in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2021, 8, 671018.	1.2	15
115	Mononuclear cell response to lipopolysaccharide in patients with rheumatoid arthritis: relationship with tristetraprolin expression. <i>Journal of Rheumatology</i> , 2005, 32, 998-1005.	1.0	15
116	Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype. <i>Clinical Immunology</i> , 2009, 131, 98-108.	1.4	14
117	Baseline Shoulder Ultrasonography Is Not a Predictive Marker of Response to Glucocorticoids in Patients with Polymyalgia Rheumatica: A 12-month Followup Study. <i>Journal of Rheumatology</i> , 2017, 44, 241-247.	1.0	14
118	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018, 85, 455-459.	0.8	14
119	Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. <i>Annals of Laboratory Medicine</i> , 2020, 40, 101-113.	1.2	14
120	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021, 88, 105062.	0.8	14
121	C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis. <i>European Journal of Internal Medicine</i> , 2022, 104, 49-54.	1.0	14
122	The B side of rheumatoid arthritis pathogenesis. <i>Pharmacological Research</i> , 2019, 149, 104465.	3.1	13
123	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14755.	0.8	13
124	Autoantibodies and thrombophilia in RA: TNF $\alpha$ and TNF $\beta$ blockers. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 613-615.	0.5	12
125	The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU). <i>Medicine (United States)</i> , 2016, 95, e5506.	0.4	12
126	Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 351-359.	0.6	11



#	ARTICLE	IF	CITATIONS
127	Basic immunology may lead to translational therapeutic rationale: SARS-CoV-2 and rheumatic diseases. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13342.	1.7	11
128	Comprehensive review on intravertebral intraspinal, intrajoint, and intradiscal vacuum phenomenon: From anatomy and physiology to pathology. <i>Modern Rheumatology</i> , 2021, 31, 303-311.	0.9	11
129	High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. <i>Clinical Rheumatology</i> , 2014, 33, 31-37.	1.0	10
130	Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles of the responders. <i>Immunotherapy</i> , 2018, 10, 807-821.	1.0	10
131	Selective Inhibitors of T Cell Receptor Recognition of Antigen-MHC Complexes for Rheumatoid Arthritis. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 644-649.	1.3	10
132	Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 649-655.	0.4	10
133	Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections. <i>Reumatismo</i> , 2011, 63, 5-10.	0.4	9
134	The UltraSound-Clinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 619-629.	1.6	9
135	Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study. <i>European Journal of Internal Medicine</i> , 2019, 66, 57-61.	1.0	9
136	Comment on: Emergence of severe spondyloarthropathy-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. <i>Rheumatology</i> , 2019, 58, 1113-1115.	0.9	9
137	Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 902-903.	1.9	9
138	Biomarkers of Joint Damage in Rheumatoid Arthritis: Where Are We in 2013?. <i>Journal of Rheumatology</i> , 2013, 40, 1244-1246.	1.0	8
139	Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e31-e31.	0.5	8
140	Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement. <i>Journal of rheumatology Supplement</i> , The, 2015, 93, 65-69.	2.2	8
141	Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of Giant Cell Arteritis: Comparison with Corticosteroids Alone. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 672-374.	1.3	8
142	Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study. <i>Frontiers in Medicine</i> , 2021, 8, 613889.	1.2	8
143	Adult onset Still's disease and pregnancy. <i>Autoimmunity Reviews</i> , 2019, 18, 102356.	2.5	7
144	Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases. <i>Autoimmunity Reviews</i> , 2019, 18, 317-324.	2.5	7

#	ARTICLE	IF	CITATIONS
145	Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies. <i>Frontiers in Medicine</i> , 2020, 7, 553075.	1.2	7
146	Pulmonary intravascular coagulopathy in COVID-19 pneumonia. <i>Lancet Rheumatology</i> , The, 2020, 2, e458.	2.2	7
147	European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. <i>Rheumatology</i> , 2022, 61, 3799-3807.	0.9	7
148	Residual minimal disease activity in rheumatoid arthritis: a simple definition through an in-depth statistical analysis of the major outcome. <i>Rheumatology</i> , 2009, 48, 1242-1246.	0.9	6
149	Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES. <i>RMD Open</i> , 2016, 2, e000263.	1.8	6
150	Correspondence on "Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e5-e5.	0.5	6
151	Correspondence to "Gender gap in rheumatology: speaker representation at annual conferences" by Monga and Liew "gender discrepancies at annual EULAR congresses: towards the gap narrowing. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e169-e169.	0.5	6
152	Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e29-e29.	0.5	6
153	Basophil activation and serum IL-5 levels as possible monitor biomarkers in severe eosinophilic asthma patients treated with anti-IL-5 drugs. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1569-1571.	2.7	6
154	B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1150-3.	1.8	6
155	Pro Nerve Growth Factor and Its Receptor p75NTR Activate Inflammatory Responses in Synovial Fibroblasts: A Novel Targetable Mechanism in Arthritis. <i>Frontiers in Immunology</i> , 2022, 13, 818630.	2.2	6
156	CYCLOSPORINE A PHARMACOKINETICS IN RHEUMATOID ARTHRITIS PATIENTS AFTER 6 MONTHS OF METHOTREXATE THERAPY. <i>Pharmacological Research</i> , 1999, 40, 483-486.	3.1	5
157	Platelet GPIIb/IIIa (P1A1/2) polymorphism in SLE: clinical and laboratory association. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 781-782.	0.5	5
158	ZAP-70+ B Cell Subset Influences Response to B Cell Depletion Therapy and Early Repopulation in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 2276-2285.	1.0	5
159	Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients. <i>Reumatismo</i> , 2012, 64, 368-73.	0.4	5
160	Should rheumatoid factor (RF) (and antinuclear antibodies (ANA)) become routinary screening test for morbidities in the general population?. <i>Autoimmunity Reviews</i> , 2018, 17, 636-638.	2.5	5
161	Ultrasound assessment as predictor of disease relapse in children and adults with arthritis in clinical stable remission: new findings but still unmet needs. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1391-1393.	0.5	5
162	Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study. <i>Journal of Translational Autoimmunity</i> , 2020, 3, 100072.	2.0	5

#	ARTICLE	IF	CITATIONS
163	Psoriatic arthritis and depressive symptoms: does systemic inflammation play a role?. <i>Clinical Rheumatology</i> , 2021, 40, 1893-1902.	1.0	5
164	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab015.	0.3	5
165	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 660-665.	0.4	5
166	Demographic and clinical differences between ankylosing spondylitis and non-radiographic axial spondyloarthritis: results from a multicentre retrospective study in the Lazio region of Italy. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 88-93.	0.4	5
167	Tofacitinib for rheumatoid arthritis. <i>Lancet, The</i> , 2013, 381, 1812.	6.3	4
168	Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?. <i>Arthritis Research and Therapy</i> , 2016, 18, 126.	1.6	4
169	PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231984705.	1.1	4
170	CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 315-7.	0.4	4
171	Is Citrullination Required for the Presence of Restricted Clonotypes Reacting With Type II Collagen? Comment on the Article by Chemin et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 2052-2053.	2.9	3
172	Measuring the Tâ€cell downâ€regulation of TCRâ€zeta, ZAPâ€70 and CD28 in arthritis patients: An old tool for new biomarkers. <i>European Journal of Immunology</i> , 2019, 49, 2195-2203.	1.6	3
173	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. <i>Archives of Rheumatology</i> , 2020, 35, 163-169.	0.3	3
174	Morbidity and Mortality From COVIDâ€19 Are Not Increased Among Children or Patients With Autoimmune Rheumatic Diseaseâ€Possible Immunologic Rationale: Comment on the Article by Henderson et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 1772-1774.	2.9	3
175	Ultrasonography involvement of carotid, upper and lower limb arteries in a large cohort of systemic sclerosis patients. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 681-692.	0.9	3
176	Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 97-104.	1.4	3
177	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. <i>Clinical Rheumatology</i> , 2021, 40, 4039-4047.	1.0	3
178	Compassionate use of anti-IL6 receptor antibodies in critically ill patients with acute respiratory distress syndrome due to SARS-COV-2. <i>Minerva Anestesiologica</i> , 2021, 87, 1080-1090.	0.6	3
179	Using a modified Delphi process to establish clinical consensus for the diagnosis, risk assessment and abatacept treatment in patients with aggressive rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 772-776.	0.4	3
180	Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 73-84.	0.4	3

#	ARTICLE	IF	CITATIONS
181	Infectious agents breaking the immunological tolerance: The holy grail in rheumatoid arthritis reconsidered. <i>Autoimmunity Reviews</i> , 2022, 21, 103102.	2.5	3
182	Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 427-428.	0.5	2
183	Should We Consider Tumor Necrosis Factor as the Only Target in Spondyloarthritis?. <i>Journal of rheumatology Supplement, The</i> , 2012, 89, 94-96.	2.2	2
184	The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. <i>Autoimmunity Reviews</i> , 2018, 17, 1251-1258.	2.5	2
185	Adult Onset Still's Disease and Radiotherapy treatment for breast cancer: Case report about management of this rare association and literature review. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 527-532.	0.3	2
186	HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?. <i>RMD Open</i> , 2020, 6, e001171.	1.8	2
187	Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e157-e157.	0.5	2
188	Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 1084-1091.	0.4	2
189	High CD14+ peripheral monocytes expression of ALX/FPR2 and BLT1 in low disease activity and remission status in rheumatoid arthritis: a pilot study. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	2
190	B cell depletion and a T cell-targeted therapy allows to control the sudden onset of diabetes and lupus, without steroids. <i>Acta Diabetologica</i> , 2008, 45, 195-196.	1.2	1
191	Weight Loss, The Obesity Paradox in Rheumatoid Arthritis: Is It a Paradox? Comment on the Article by Baker et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 553-553.	2.9	1
192	Comment on "Tumor necrosis factor- $\alpha$ antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study" Clinical Rheumatology, 2016, 35, 839-840.	1.0	1
193	Statins and Mortality in Connective Tissue Diseases: Should We Resume the Cardio-rheumatology Spirit in Our Clinics?. <i>Journal of Rheumatology</i> , 2018, 45, 1617-1619.	1.0	1
194	Diagnostic performance of FDG PET in large vessel vasculitis. <i>Clinical and Translational Imaging</i> , 2019, 7, 415-425.	1.1	1
195	Correspondence on "Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry" by Gianfrancesco M et al. The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e159-e159.	0.5	1
196	Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 1782-1783.	0.9	1
197	RAASI, NSAIDs, antidiabetics, and anticoagulants: More data needed to be labeled as harmful or neutral in SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2025609118.	3.3	1
198	Factors predicting early discontinuation of methotrexate as a first-line treatment for rheumatoid arthritis in Italy: Results from the GISEA registry. <i>Indian Journal of Rheumatology</i> , 2019, 14, 271.	0.2	1

#	ARTICLE	IF	CITATIONS
199	Patterns of Anti-Inflammatory and Immunomodulating Drug Usage and Microvascular Endothelial Function in Rheumatoid Arthritis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 681327.	1.1	1
200	An unusual lung involvement in scleroderma: lipoid pneumonia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 161-162.	0.4	1
201	Chapter 8 Gastrointestinal Involvement in Systemic Vasculitis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008, 8, 83-298.	0.1	0
202	Association of autoimmune diseases to allele 2 of the 3' immunoglobulin HS1.2 enhancer bearing an NF- $\kappa$ B binding site.. <i>Nature Precedings</i> , 2009, , .	0.1	0
203	03.13â€¦Synovial tissue of ra patients in remission contains a unique population of regulatory macrophages. , 2017, , .		0
204	AB0253â€¦BIOMARKERS OF CLINICAL RESPONSE TO IL6-R BLOCKADE IN DMARDS INCOMPLETE RESPONDERS (AR-BIOM TRIAL): IL23 AND BAFF AS BIOLOGICAL TARGETS, AND ALBUMIN AS BIOLOGICAL PREDICTOR. , 2019, , .		0
205	SAT0090â€¦GUT MICROBIOTA COMPOSITION IS CONTINGENT WITH DISEASE PHASES IN RHEUMATOID ARTHRITIS. , 2019, , .		0
206	O14â€¦Semi-quantitative assessment of synovial inflammation on US guided synovial membrane biopsy is contingent to disease phase, autoimmune profile and treatment response in RA: a large single center experience. <i>Rheumatology</i> , 2020, 59, .	0.9	0
207	P234â€¦Characterisation of human synovial tissue dendritic cells in rheumatoid arthritis patients. <i>Rheumatology</i> , 2020, 59, .	0.9	0
208	No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic. <i>Rheumatology</i> , 2020, 59, 2644-2646.	0.9	0
209	Simultaneous Onset of <i>Mycobacterium kansasii</i> Pulmonary Infection and Systemic Lupus Erythematosus: A Case Report. <i>American Journal of Case Reports</i> , 2021, 22, e929866.	0.3	0
210	Depression and Endothelial Dysfunction in Psoriatic Arthritis: Is There Any Possible Relationship?. <i>Frontiers in Medicine</i> , 2021, 8, 669397.	1.2	0
211	Rheumatologic Symptoms in Patients with Mixed Cryoglobulinemia. , 2012, , 185-190.		0
212	Reply to: Individuality of the composition of the human microbiota by FernÃ¡ndez-EstupiÃ±n et al. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 128, 34.	0.4	0
213	An unusual lung involvement in scleroderma: lipoid pneumonia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 161-162.	0.4	0
214	High CD14+ peripheral monocytes expression of ALX/FPR2 and BLT1 in low disease activity and remission status in rheumatoid arthritis: a pilot study. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
215	MO038: Mineral bone density assessment in patients affected by cystinuria. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0